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a  b  s  t  r  a  c  t
Background:  Insulin  resistance  (IR)  is a predictor  of  cardiovascular  (CV)  events  even  before  the  onset  of
diabetes.  However,  it is unclear  whether  changes  in IR after  a reduction  of  atherosclerotic  burden  may
affect  long-term  outcome  in  patients  with  coronary  artery  disease  (CAD).  This  study  examined  whether
changes  in  IR after  therapy  to  reduce  atherosclerotic  risk  factors  provides  prognostic  information  on
future  CV events  in  non-diabetic  patients  with  CAD.
Methods  and  results:  This  study  enrolled  175  non-diabetic  patients  with  newly  diagnosed  CAD and  IR.  IR
was  deﬁned  as  the homeostasis  model  assessment  of IR (HOMA-IR)   2.5. Evaluation  of HOMA-IR  was
repeated at  entry  (1st  test)  and  6  months  after  individualized,  optimized  therapy  including  medications
and  lifestyle  changes  (2nd test).  After  the  2nd  test,  all patients  were  prospectively  followed-up  for  3 years
or until  the  occurrence  of  one  of  the  following  events:  CV  death,  nonfatal  myocardial  infarction,  unstable
angina  requiring  coronary  revascularization,  or  ischemic  stroke.  IR was  improved  (HOMA-IR  <  2.5)  after
6 months  in 71  (41%)  patients,  whereas  IR persisted  in  104  (59%)  patients.  During  the  follow-up  period,
events  occurred  in 21  (20%)  of the 104 patients  with  persistent  IR and 3  (4%) of the  71  patients  with
improved  IR  (p <  0.01).  In  multivariate  stepwise  Cox  proportional  hazards  analysis,  persistent  IR  was  an
independent  predictor  of  future  CV events  (HR  4.8,  95%  CI  1.4–11.2,  p < 0.01).
Conclusions:  The  presence  of  IR despite  optimized  therapies  to reduce  atherosclerotic  risk  factors  repre-
e  pred
3  Japsents an adverse  outcom
©  201
ntroduction
Insulin resistance (IR) is associated with hypertension, glucose
ntolerance, obesity, and dyslipidemia which are well-known risk
actors for coronary artery disease (CAD) [1–3]. IR is associated with
n increased incidence of cardiovascular disease even before the
nset of diabetes [4,5]. However, there are no guidelines for the
reatment of insulin resistance in CAD patients [6,7]. In patients that
eceive therapy to reduce atherosclerotic risk factor burden, IR can
e reversed by medications and lifestyle modiﬁcations, especially
n non-diabetic subjects [8,9]. Generally, it has been recognized that
eight reduction and increased physical activity reduce IR [10,11].
or pharmacological intervention, two classes of drugs (metformin
nd insulin sensitizers) are currently available to reduce IR [12,13].
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However, these drugs are approved for the treatment of type
2 diabetes, but not IR in Japan. Insulin sensitivity can also be
improved by drugs that reduce atherosclerotic risk factors such as
antihypertensive or lipid-lowering drugs according to the guide-
lines [14–17]. Therefore a comprehensive management approach
to reduce risk factors is needed to treat IR.
It is known that IR, as assessed by the homeostasis model assess-
ment insulin resistance (HOMA-IR), is an independent predictor
of cardiovascular disease, and a one unit increase in the HOMA-
IR value is associated with a 5.4% increase in cardiovascular risk
[18]. Although most previous studies showed that the assessment
of IR at only a single time point predicts future cardiovascular
events [18–23], a single assessment of IR may not necessarily
reﬂect later insulin sensitivity, because a reduction in risk factors
improves insulin sensitivity. In addition, IR measured at a single
time point may  not reﬂect long-term progression of atheroscle-
rotic disease. Only a few studies have evaluated prognosis based
on serial measurements of IR. Katayama et al. tested the prognostic
role of reversing IR in non-diabetic patients with CAD [24]. However
that report assessed in-stent restenosis, but did not assess future
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ardiovascular events. Moreover, it remains unknown whether
here is an association between reversible IR and a favorable out-
ome in non-diabetic patients with CAD. Thus, this study examined
hether changes in IR after therapy for atherosclerotic burden pro-
ides prognostic information on future cardiovascular events in
on-diabetic patients with CAD.
ethods
tudy patients
This study enrolled 175 patients from a population of 499
on-diabetic patients with newly diagnosed CAD who  were admit-
ed to Yamanashi University Hospital for coronary angiography
rom April 2003 to March 2007. The inclusion criteria included an
mpaired IR (HOMA-IR ≥ 2.5) at enrollment and the assessment of
R repeated 6 months after enrollment. Diabetes mellitus (DM) was
eﬁned according to the criteria of the American Diabetic Associa-
ion [25]. All patients had angiographic documentation of organic
tenosis of >70% of at least one major coronary artery (176 patients
ad single-vessel disease, 228 had two-vessel disease, and 95 had
hree-vessel disease). Patients were excluded based on the pres-
nce of any of the following criteria: (1) stroke, cardiogenic shock,
ulmonary edema, major surgery, trauma, or serious infectious dis-
ase within 4 weeks prior to enrollment and during 6 months; (2)
ew York Heart Association classiﬁcation ≥ III; (3) left main trunk
isease; (4) left ventricular ejection fraction < 30%; (5) neoplasm,
hronic hepatic or inﬂammatory diseases; (6) chronic renal failure
serum creatinine levels > 2.0 mg/dL); and (7) other serious sys-
emic diseases. Among the 499 eligible patients, 324 patients were
xcluded because they did not have IR. The characteristics of the
tudy patients are shown in Table 1. This study was in agreement
ith the guidelines approved by the ethics committee at our insti-
ution. Written informed consent was obtained from all patients
efore the study. The investigation conformed to the principles
utlined in the 1975 Declaration of Helsinki.
tudy protocolWe  evaluated glucose and insulin levels at baseline in the
orning after an overnight fast before coronary angiography
1st test) and at 6 months after the 1st test (2nd test). After
nrollment, all patients had individualized, optimized therapies
able 1
omparison of clinical characteristics of patients with IR at the 1st examination.
Persistent IR (n = 104) Improved IR (n = 71)
Age (years) 64 ± 12 66 ± 12
Male sex (%) 79 66
Hypertension (%) 68 66
Current smoker (%) 43 39
Multivessel CAD (%) 48 49
Family history (%) 17 14
Body mass index (kg/m2) 26 ± 3.3 25 ± 3.2
Systolic BP (mmHg) 143 ± 23 142 ± 19
HbA1c (%) 5.7 ± 0.4 5.6 ± 0.3
Fasting glucose (mg/dL) 104 ± 13 107 ± 15
Fasting IRI (U/mL) 14.4 ± 4.1 13.6 ± 4.9
Hs CRP (mg/dL) 0.22 (0.10, 0.41) 0.22 (0.10, 0.30)
LDL-C (mg/dL) 121 (101, 148) 125 (111, 146)
HDL-C (mg/dL) 41 ± 9 43 ± 11
Triglycerides (mg/dL) 159 (112, 205) 130 (91, 194)
ata are expressed as mean ± SD or percentage of the patients. IR, HOMA-IR ≥ 2.5;
ypertension, ≥140/90 mmHg  or taking antihypertensive medication; smoking,
10 cigarettes/day for ≥10 years; IR, insulin resistance; CAD, coronary artery dis-
ase; BP, blood pressure; HbA1c, hemoglobin A1c; IRI, immune-reactive insulin; Hs
RP,  high sensitive C-reactive protein; LDL-C, low-density lipoprotein cholesterol;
DL-C, high-density lipoprotein cholesterol.logy 62 (2013) 348–353 349
including medication and lifestyle changes to reduce risk factors
for CAD according to the American Heart Association/American
College of Cardiology guidelines [6,7]. The target for low-density
lipoprotein cholesterol (LDL-C)-lowering therapy was  <100 mg/dL
(2.6 mmol/L) and hypertension control was  a blood pressure
<140/90 mmHg. All patients were advised to maintain or reduce
waist circumference to <85 cm in men  and <90 cm in women
through an appropriate balance of physical activity (walk-
ing > 30 min/day) and caloric intake according to The Examination
Committee of Criteria for Obesity Disease in Japan [26]. All patients
were followed-up in the hospital or with a clinic visit every month
and encouraged to adhere to the lifestyle changes and diet recom-
mendations. Also all patients did not receive anti-diabetic drugs.
Blood assays
Venous blood was  obtained from all study patients after a 12 h
overnight fast at the time of enrollment into the study. Levels of
high density lipoprotein cholesterol (HDL-cholesterol) and LDL-
cholesterol in fasting serum were measured as described previously
[27]. High sensitive C-reactive protein (Hs CRP) levels in the fas-
ting plasma were assayed by rate nephelometry (Dade Behring,
Marburg, Germany). Plasma glucose was  measured by the glucoki-
nase method. Fasting insulin concentrations were measured with a
commercial double-antibody radioimmunoassay (human-insulin-
speciﬁc radioimmunoassay method, LINCO Research, St. Louis, MO,
USA). An estimate of IR was  calculated using HOMA-IR as fol-
lows: IR = fasting plasma glucose (mg/dL) × fasting plasma insulin
(U/mL)/405 [28].
Follow-up study
After the 2nd test, all of the 175 patients with CAD were
followed-up every month in the hospital or with a clinic visit for
up to 36 months or until the occurrence of one of the following
clinical cardiovascular disease (CVD) events: cardiac death, nonfa-
tal myocardial infarction, recurrent or refractory angina pectoris
requiring coronary revascularization by percutaneous coronary
intervention or coronary artery bypass surgery, or ischemic stroke.
The time to the ﬁrst CVD event was  evaluated prospectively. The
diagnosis of myocardial infarction was made by chest pain, appear-
ance of new Q waves in the electrocardiogram and elevation of
plasma creatine kinase to more than twice the upper limit of nor-
mal. The cause of death was determined from hospital records.
All endpoint data were checked for accuracy, consistency, and
completeness of follow-up by two  of the investigators (J.O., J.D.)
without knowledge of the patients’ baseline characteristics. Addi-
tional information was  obtained from the physicians as needed.
Two of the investigators (D.F., K.Ka.) were also responsible for
checking all data, running the analysis, and the security of the
data ﬁles. The same medications prescribed during the 6 months
between the 1st and 2nd tests were continued in each patient. All of
the study patients were encouraged every month to adhere to the
recommended diet and lifestyle changes throughout the follow-up
period.
Statistical analysis
Data are expressed as the mean value ± SD, median and range
(25 and 75th percentiles) or frequencies (%). The Shapiro–Wilk
test showed that levels of Hs CRP, LDL-C, and TG were not dis-
tributed normally. Therefore, these data are expressed as the
median and inter-quartile range (25 and 75th percentiles) and were
log-transformed for statistical analysis. Continuous variables were
compared between the 2 groups of patients using a Student’s paired
or unpaired t test and categorical variables were compared using a










































Comparison of the clinical characteristics of patients with IR at the 2nd examination.
Persistent IR (n = 104) Improved IR (n = 71)
Continuing smoking (%) 37 (15/41) 8 (2/25)*
Body mass index (kg/m2) 25 ± 3.3 25 ± 2.7
Systolic BP (mmHg) 136 ± 24 135 ± 23
HbA1c (%) 5.7 ± 0.6 5.6 ± 0.5
Fasting glucose (mg/dL) 108 ± 24 95 ± 10*
Fasting IRI (U/mL) 15 ± 6 6.4 ± 2*
Hs  CRP (mg/dL) 0.08 (0.03, 0.18) 0.05 (0.03, 0.12)
LDL-C (mg/dL) 100 (84, 124) 106 (85, 124)
HDL-C (mg/dL) 42 ± 9 44 ± 11
Triglycerides (mg/dL) 143 (115, 184) 126 (97, 176)
% Change in risk status from the 1st to the 2nd test
Body mass index (kg/m2) −0.1 −2
Systolic BP (mmHg) −4 −2
HbA1c (%) 1 −1
Hs CRP (mg/dL) 55 −1
LDL-C (mg/dL) −13 −13
HDL-C (mg/dL) 6 5
Triglycerides (mg/dL) −4 −12
Data are expressed as mean ± SD or percentage of the patients. IR, HOMA-IR ≥ 2.5;
to 36 months, mean 31 ± 4 months). Patients with persistent IR
had 20 (19%) cardiovascular events (1 cardiac death, 3 nonfatal
myocardial infarctions, 13 recurrent angina pectoris that required
coronary revascularization, and 3 had strokes) during the follow-up
Table 350 Y. Kitta et al. / Journal of 
hi-square test. Kaplan–Meier analysis of event-free survival dur-
ng follow-up was performed with patients stratiﬁed based on the
hange in IR. The association of IR with future events was assessed
y Cox proportional hazards analysis. The data were analyzed
nitially using a univariate model with covariates (IR and other
otential confounders) that were signiﬁcantly different between
atients with and without events. Multivariate analysis was then
pplied using the covariates that were signiﬁcantly associated with
vents in the univariate analysis. The Cox proportional hazard anal-
sis included confounders that had proportionalities that were
valuated by the Schoenfeld residuals test. Based on generally
ccepted modeling constraints, one covariate can be included in the
ultivariable model for each 10 outcome events. Thus, the mul-
ivariate Cox proportional hazard analysis was performed using
ultiple models when the number of the cardiovascular events
as small. A p-value of <0.05 was considered statistically signif-
cant. Analyses were performed with StatView 5.0 (SAS Institute,
ary, NC, USA) and STATA version 10.0 (StataCorp, College Station,
X, USA).
On the basis of our preliminary observations, we suspected
hat the composite endpoint would occur in approximately 20%
f patients with persistent IR and in 5% of those with improved
R during 36 months of follow-up. Thus, it was estimated that 72
atients would be needed in each group (n = 144, total) to detect
 signiﬁcant difference in events between the two  groups with a
wo-tailed  ˛ of 0.1 and a power of 0.80 (  ˇ = 0.20).
esults
OMA-IR
At the 2nd test, 104 patients had persistent IR (HOMA-IR ≥ 2.5),
hereas the remaining 71 patients had signiﬁcantly improved IR
HOMA-IR < 2.5), as shown in Fig. 1. The baseline HOMA-IR at the
st test was comparable between patients with persistent IR and
hose with improved IR (Table 1). Fasting glucose levels were not
igniﬁcantly different between the two groups at either the 1st or
he 2nd test (Table 2).
omparison of clinical variables at 1st and 2nd test between
atients with persistent IR and those with improved IRProﬁles of atherosclerotic risk factors except continuing smok-
ng, fasting glucose, and fasting immune-reactive insulin at the
st and 2nd tests were comparable between the two groups
ig. 1. Comparison of the homeostasis model assessment of insulin resistance
HOMA-IR) value between the 1st and 2nd test. *p < 0.01 vs. 1st test in patients
ith improved insulin resistance (IR).IR,  insulin resistance; BP, blood pressure; HbA1c, hemoglobin A1c; IRI, immune-
reactive insulin; Hs CRP, high sensitive C-reactive protein; LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
(Tables 1 and 2). In addition, the frequency of cardiovascular med-
ications used at the 1st and 2nd tests, and dosage changes or
the addition of new medications immediately after the 1st test
were comparable between the two  groups (Table 3). Proﬁles of
atherosclerotic risk factors at the 2nd test were similarly improved
from their baseline values at the 1st test, and the target achieve-
ment rates for blood pressure control, LDL-C, levels and HbA1c
levels at the 2nd test were similar between the two groups (Table 2).
Prognostic value of HOMA-IR in CAD patients
All of the 175 patients completed the follow-up study (from 2Comparison of medication usage.
Persistent IR (n = 104) Improved IR (n = 71)
Medications before the 1st examination
Statin (%) 14 10
ACE-I (%) 6 10
ARB (%) 21 22
Ca blocker (%) 12 18
-Blocker (%) 8 8
Aspirin (%) 29 30
Medications added or increased after the 1st examination
Statin (%) 52 53
ACE-I (%) 9 10
ARB (%) 34 36
Ca blocker (%) 40 45
-Blocker (%) 8 8
Aspirin (%) 68 66
Medications at the 2nd examination
Statin (%) 59 54
ACE-I (%) 13 17
ARB (%) 59 45
Ca blocker (%) 55 63
-Blocker (%) 15 16
Aspirin (%) 100 100
IR, HOMA-IR ≥ 2.5; IR, insulin resistance; ACE-I, angiotensin-converting enzyme
inhibitor; ARB, angiotensin receptor blocker. Patients with persistent IR and
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eriod, whereas patients with improved IR had 3 (4%) events (2 had
ecurrent angina pectoris that required coronary revascularization,
nd 1 had stroke) (p < 0.01). Kaplan–Meier analysis demonstrated
hat patients with persistent IR had signiﬁcantly lower event-free
urvival than patients with improved IR (p < 0.01 by log-rank test)
Fig. 2). Among the clinical variables listed in Table 1, age and
RP levels at the 2nd test were signiﬁcantly higher in patients
ith than without an event. Furthermore, the frequency of per-
istent IR (HOMA-IR ≥ 2.5 at the 2nd test) was signiﬁcantly higher
n patients with than without an event. The baseline HOMA-IR at
he 1st test was comparable between patients with and without an
vent. In a univariate Cox proportional hazards model, persistent
R, Hs CRP levels at the 2nd test, and age were signiﬁcant predictors
f events among the variables that showed a signiﬁcant difference
etween patients with and without an event (Table 4). A multivari-
te Cox proportional hazards model demonstrated that persistent
R remained a signiﬁcant independent predictor of future events
Table 4). The baseline HOMA-IR at the 1st test had no signiﬁcant
redictive value in the univariate Cox proportional hazards model
HR 1.1, 95% CI 0.8–1.4, p = 0.62).
iscussionThis present study showed that persistent IR despite therapies
o reduce atherosclerotic risk factors was an independent predictor
f future cardiovascular events in non-diabetic patients with CAD.
ig. 2. Kaplan–Meier curves of event-free survival based on the change in insulin
esistance (IR) in response to risk factor reduction during the follow-up period
mean, 31 ± 4 months) in 175 patients with coronary artery disease (104 patients
ad persistent IR, and 71 patients had improved IR).
able 4
nivariate Cox proportional hazards analysis of risk factors for cardiovascular events.
Univariate 
HR 95% CI 
Persistent IR 4.8 1.4–16 
Hs  CRP at the 2nd exam 2.8 1.4–8.4 
Age  1.1 1.0–1.1 
Continuing smoking 1.9 0.7–4.8 
Hypertension 2.0 0.9–4.1 
Hyperlipidemia 1.1 0.8–1.4 
Family History 1.4 0.6–3.3 
Multivessel disease 1.4 0.6–2.5 
Fasting glucose at 2nd exam 1.4 0.6–3.2 
HOMA-IR at the 1st exam 1.2 0.6–2.5 
HbA1c at the 2nd exam 1.0 0.9–1.0 
R, hazard ratio; CI, conﬁdence interval; exam, examination; IR, insulin resistance; Hs CRlogy 62 (2013) 348–353 351
Periodic measurement of IR may  be useful for risk stratiﬁcation in
non-diabetic patients with CAD. In contrast, the baseline HOMA-IR
before the use of therapies to reduce risk factors did not provide sig-
niﬁcant prognostic information in non-diabetic patients with CAD
in the present study. Patients with persistent IR may  need more
intensive risk factor modiﬁcation to reduce future cardiovascular
events.
There may  be several reasons for the negative value of base-
line IR in the present study. The selection of patients with CAD
and IR at baseline may  partly account for the negative predictive
value of IR at baseline. IR is affected by several factors that are
associated with CVD [1,2]. However, IR can be altered by modi-
ﬁcation of atherosclerotic risk burden [8,9]. To date, most patients
with CAD have optimized therapy for reduction of atherosclerotic
risk factors according to guidelines and evidence established from
many clinical trials. Thus, the predictive value of IR for future CVD
events may  be considerably inﬂuenced by the anti-atherosclerotic
treatment initiated after baseline. The present patient population
consisted of newly diagnosed patients with CAD, and most of them
did not have optimal treatment to reduce atherosclerotic risk fac-
tors at the time of the baseline test. However, the improvement
in the risk-factor proﬁle after the 6 months of optimized therapy
was associated with the improvement of insulin sensitivity at the
2nd test in patients with improved IR. In these patients, the pres-
ence of IR at baseline did not reﬂect the severity of CAD and the
atherosclerotic risk burden. This may  be another reason for the
negative predictive value of baseline IR. Therefore, it is reason-
able that a change in insulin sensitivity in response to risk factor
modiﬁcation may  be a better predictor of future cardiac events
than the presence of IR at baseline in non-diabetic patients with
CAD.
It is known that risk factor reduction to target levels after
optimized therapy does not necessarily prevent future cardio-
vascular events in all CAD patients. The presence of IR despite
optimized therapies to reduce atherosclerotic risk factors may
be a residual risk factor. It remains unknown what mechanisms
may  explain the different responses of the follow up IR to the
similar anti-atherosclerotic treatments and atherosclerotic burden
in this study. Undetermined risk factors or genetic predisposi-
tion may  play a role in the improvement in IR in response to
therapy. Therefore, therapeutic intervention is needed to target
IR even in non-diabetic patients. Previous reports showed that
drug therapy such as metformin and insulin sensitizers reduced
CV events in patients with DM [29–31]. Those patients with IR
despite optimized therapies to reduce atherosclerotic risk factors
may  need to use such medications. However, combined therapy
(e.g. angiotensin receptor blocker, angiotensin-converting enzyme
inhibitor, statin, or ezetimibe) may  be better than monother-
apy.
Multivariate
p-Value HR 95% CI p-Value
0.01 4.8 1.4–11 0.01
0.01 2.8 1.1–6.9 0.02
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tudy limitations
The present study has several limitations. First, this study is pre-
iminary and considerably limited by the small number of study
atients, and that reduces the power of the statistical analyses. A
arge prospective trial is required to understand the precise role
f persistent IR in the pathogenesis and progression of atheroscle-
otic disease. Second, the anti-atherosclerotic treatments were not
ptimal in some of the patients in the present study. However, it
as unlikely that insufﬁcient risk reduction was the main cause
f failure to improve IR, because the rate of achievement of the
arget levels of risk factors was similar between the patients with
ersistent IR and improved IR. Third, IR can be assessed by vari-
us means. The hyperinsulinemic-euglycemic clamp test has been
ccepted as the gold standard to measure insulin resistance accu-
ately [32]. However, this test is difﬁcult to apply in clinical practice.
he HOMA-IR index is highly correlated with the hyperinsulinemic-
uglycemic clamp test, and its clinical usefulness has been well
stablished. Therefore the HOMA-IR was used to assess insulin
esistance in this study.
onclusion
In conclusion, persistent IR may  be related to future cardiovas-
ular events despite well-established anti-atherosclerotic therapy
n CAD patients. Periodic measurement of IR may  be useful for risk
tratiﬁcation of CAD patients.
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